Mechanistically, these alterations likely contribute to shifting TGF-β signaling from tumor-suppressive to pro-oncogenic activity, consistent with its established role in promoting epithelial-to-mesenchymal transition, immune evasion, and chemoresistance. The gene discussed is TGFB1; the disease is neoplasm.